

The 14th Annual
**John Vane
Memorial
Symposium**

on Prostacyclin Science and
Pulmonary Vascular Disease

8–9 March 2019

Foreward by Professor Chris Thiemermann, FMedSci



Dear Friends and Colleagues,

I warmly welcome you to the 14th John Vane Memorial Symposium on Prostacyclin Science and Pulmonary Vascular Disease here at The Royal Society. I would also, once again, like to thank United Therapeutics for their valued support of the series by the provision of an unrestricted educational grant.

We are delighted to provide you with a varied scientific programme which showcases the very latest research and clinical advances in PAH. This year's programme covers amongst other topics, recent research developments including the resolution of inflammation, the role that the human immune system plays and the contribution that omics profiling makes to identifying novel pathways and targets in PAH. We also will explore advances in gene therapy, new strategies for the administration of prostanoids and the importance of lowering mPAP as a treatment goal. On Saturday morning, there will be an interesting panel debate with key members and the audience, focusing on the latest 'hot' topics in pulmonary hypertension and transplantation.


I want to say a little about Professor Gustav (Gus) Born FRS, who was one of the Founding Directors of the William Harvey Research Institute and, indeed, our company, William Harvey Research Ltd, who sadly passed away in April last year. Prior to joining John Vane at the WHRI, Gus was the Head of Department at the Royal College of Surgeons in which Sir John had earlier worked. To me, Gus was an important mentor when I was a young academic and director in the company, and he was always prepared to offer his wisdom and support. Gus's great enthusiasm for research, even when he reached the age of 96, and his caring friendship will be sorely missed by us at the William Harvey.

All of WHRL Conference organising team and myself wish you a productive and highly-enjoyable few days here at the Royal Society.

With warmest regards,
Chris

A handwritten signature in blue ink, appearing to read 'C. Thiemermann'.

Professor Chris Thiemermann, MD PhD FBPhS FRCP FMedSci
Contact: c.thiemermann@qmul.ac.uk




Sir John Vane, FRS, Nobel Laureate

"In many countries now, research in universities is under severe financial restraint. This is a short-sighted policy. Ways have to be found to maintain university research untrammelled by requirements of forecasting application or usefulness. Those who wish to study the sex-life of butterflies, or the activities associated with snake venom or seminal fluid should be encouraged to do so. It is such improbable beginnings that lead by convoluted pathways to new concepts and then, perhaps some 20 years later, to new types of drugs."

A handwritten signature in purple ink, appearing to read 'John Vane'.

Speech at the Nobel Banquet
December 10, 1982



Friday, 8th March 2019

| | |
|-------------|--------------------------------------------------------------------------|
| 08.15-09.15 | Registration, tea and coffee |
| 09.15 | Welcome Chris Thiemermann, Queen Mary University of London, UK |

Session I

| | |
|----------------|------------------------------------------------------------------------------------------------------------------|
| Chairs: | Chris Thiemermann Brendan Whittle |
| 09.30 | Resolution of Inflammation Mauro Perretti, Queen Mary University of London, UK |
| 10.00 | Role of the Human Immune System in PAH Wolfgang Kuebler, Charite Berlin, Germany |
| 10.30 | Omics Profiling for Novel Pathways and Targets in PAH Christopher Rhodes, Imperial College, London, UK |
| 11.00 | Refreshments |

Session II

| | |
|----------------|------------------------------------------------------------------------------------------------------------------------|
| Chairs: | Olivier Sitbon Jim White |
| 11.30 | Identification of Rare Sequence Variation Underlying Heritable PAH Nick Morrell, University of Cambridge, UK |
| 12.00 | Lessons Learned from Drugs inducing Pulmonary Hypertension Marc Humbert, Université Paris-Sud, France |
| 12.30 | Lunch |

Session III

| | |
|----------------|-----------------------------------------------------------------------------------------------------------|
| Chairs: | Bob Bourge Duncan Stewart |
| 14.00 | New Insights into the Pathophysiology of PAH Kurt Stenmark, University of Colorado, Denver, USA |
| 14.30 | Obesity and Pulmonary Hypertension Olivier Sitbon, Université Paris-Sud, France |
| 15.00 | Lowering mPAP as Treatment Goal in PAH? Hiromi Matsubara, Okayama University, Japan |
| 15.30 | Refreshments |

Session IV

| | |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| Chairs: | Marc Humbert Irene Lang |
| 16.00 | Advances in Gene Therapy for PAH Duncan Stewart, Ottawa Hospital Research Institute, Canada |
| 16.30 | Early and Aggressive Treatment in PAH: Time for RV Integration to Risk Assessment Roberto Badagliacca, Sapienza University of Rome, Italy |
| 17.00-18.30 | Meeting adjournment and evening reception at The Royal Society |

Saturday, 9th March 2019


| | |
|------------|----------------|
| 08.00-9.30 | Tea and coffee |
|------------|----------------|

Session V

| | |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Chairs: | Stephan Rosenkranz Kurt Stenmark |
| 09.30 | The Challenging Management of PAH with Comorbidities Stephan Rosenkranz, University of Cologne, Germany |
| 10.00 | Balloon Angioplasty, a Modern Interventional Treatment of CTEPH Irene Lang, Medical University of Vienna, Austria |
| 10.30 | New Strategies for the Administration of Prostanoids in PAH: Improved patient satisfaction and lower resistance to their use? Bob Bourge, University of Alabama, Birmingham, USA |
| 11.00 | Refreshments |

Session VI

| | |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 11.30 | Freedom EV: The climb is done... what can we see from the summit? Jim White, University of Rochester, USA |
| 12.00 | Debate: Hot Topics in Pulmonary Hypertension and Transplantation Paul Corris, University of Newcastle, UK Irene Lang, Medical University of Vienna, Austria Nick Morrell, University of Cambridge, UK Sir Magdi Yacoub, The Magdi Yacoub Institute, Imperial College, London, UK |
| 13.00 | Lunch |
| 14.00 | Close of meeting |



13th John Vane Memorial Symposium (JVMS)

More than 24 nationalities participated at the 13th John Vane Memorial Symposium at The Royal Society in London in March 2018. We were delighted to welcome returning colleagues alongside many first-time delegates, all of whom came together to learn about the very latest developments in PAH.

The scientific programme, which was extremely well received, covered topics ranging from pathophysiology to risk assessment, prognosis, guideline implementation and patient stratification in patients with PAH to regulatory aspects relating to the registration of orphan drugs in PAH.

We would like to extend our thanks, once again, to everyone who contributed to the success of the symposium and for their valued contribution.

Here are some pictures from the 2018 symposium.



Professor Dario Vizza



Lady Vane



Friends and colleagues



Members of the 2018 delegation



Discussions between lectures



2018 Speaker faculty

William Harvey Research Limited®

Contract Research

WHRL, in addition to organising scientific conferences, has been leading the way as a preclinical contract research organisation (CRO) for the pharmaceutical and biotechnology sectors for over 25 years. Offering more than 120 *in vivo* and *in vitro* disease models across therapeutic areas, our expert team of academics from the prestigious, world-renowned William Harvey Research Institute in London provide bespoke study design, specialised advice, one-to-one discussions, comprehensive reports of research findings including full statistical analysis and interpretation of data, and long-term collaboration with strategic partners. With extensive expertise in models of inflammation and the cardiovascular system including hypertension, among many others, our team provides tailor made solutions for drug discovery.

Shareholders

WHRL is a business wholly committed to furthering preclinical research into cardiovascular disease and inflammation for translational and therapeutic purposes. Its profits are gift aided to its majority shareholder, the William Harvey Research Foundation, which in turn awards grants for such preclinical research. Grants amounting to over £10m have been awarded by the WHRF to date. WHRL works primarily but not exclusively at the central London facilities of the William Harvey Research Institute at Barts and the London School of Medicine, Queen Mary University of London, WHRL's minority shareholder.

Brand & Website


William Harvey Research® is a trademark owned by WHRL. The company also owns the trademark for William Harvey Conferences®, William Harvey Heart®, and William Harvey Consulting® to name a few. In November 2018, following a year long process of brand revitalisation for logo, icons and images, WHRL launched its new website. Please do follow the link below.

www.williamharveyresearch.com



8-9 March 2019

Royal Society, London, UK



Faculty Chair

Chris Thiernemann, Queen Mary University of London, UK

Session Chairs and Panel Discussants:

Bob Bourge

University of Alabama,
Birmingham, USA

Paul Corris

University of Newcastle, UK

Marc Humbert

Université Paris-Sud, France

Irene Lang

Medical University of Vienna, Austria

Nick Morrell

University of Cambridge, UK

Stephan Rosenkranz

University of Cologne, Germany

Kurt Stenmark

University of Colorado, Denver, USA

Duncan Stewart

Ottawa Hospital Research Institute, Canada

Olivier Sitbon

Université Paris-Sud, France

Jim White

University of Rochester, USA

Brendan Whittle

Queen Mary University of London, UK

Sir Magdi Yacoub

The Magdi Yacoub Institute,
Imperial College, London, UK



The '14th John Vane Memorial Symposium on Prostacyclin Science and Pulmonary Vascular Disease' has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 8 category 1 (external) CPD credit(s).

William Harvey Research Limited

John Vane Science Centre
Charterhouse Square
London
EC1M 6BQ
United Kingdom
Tel: +44 (0)20 7882 8808
Email: whrl@qmul.ac.uk

 @JVMSSeries

 @JVMSSeries

 @JVMSSeries